Cargando…
No crossreactivity of anti-SARS-CoV-2 spike protein antibodies with Syncytin-1
Autores principales: | Prasad, Mukul, Lin, Jia Le, Gu, Yue, Gupta, Rashi, Macary, Paul, Schwarz, Herbert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8513556/ https://www.ncbi.nlm.nih.gov/pubmed/34645941 http://dx.doi.org/10.1038/s41423-021-00773-x |
Ejemplares similares
-
Potential for false decline of anti-SARS-CoV-2 spike antibody titers after COVID-19 vaccination
por: Waldman, Meryl, et al.
Publicado: (2022) -
Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2 compared to SARS-CoV
por: Zheng, Ming, et al.
Publicado: (2020) -
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
por: Jangra, Sonia, et al.
Publicado: (2021) -
Immunogenicity and crossreactivity of antibodies to the nucleocapsid protein of SARS-CoV-2: utility and limitations in seroprevalence and immunity studies
por: Dobaño, Carlota, et al.
Publicado: (2021) -
Identification and characterization of a monoclonal antibody blocking the SARS-CoV-2 spike protein–ACE2 interaction
por: Yuan, MengYa, et al.
Publicado: (2021)